THZ1
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
THZ1是一种CDK7的共价抑制剂,IC50值为3.2 nM。
THZ1能够靶向共价修饰CDK7激酶结构域外的C312残基。在激酶结合试验中,THZ1表现出良好的亲和性,IC50值为3.2 nM。THZ1可以有效地抑制Jurkat和Loucy T-ALL细胞的生长,IC50值分别为50 nM和0.55 nM。据报道,THZ1在Jurkat和Loucy细胞中扰乱CDK7信号通路。针对各种癌细胞系,THZ1展示了低于200 nM的IC50值的广泛活性。在这些细胞系中,T-ALL对THZ1表现出了特殊的敏感性,这是由于THZ1引起的RUNX1的转录效应。
作为CDK7的抑制剂,THZ1可以抑制CDK蛋白的激活。THZ1也可以抑制RNA聚合酶II的C-末端结构域的磷酸化,从而影响转录调控。
参考文献:
[1] Nicholas Kwiatkowski, Tinghu Zhang, Peter B. Rahl et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature, 2014.
- 1. Anh Phuong Nguyen, Kaoru Yamagata, et al. "Enhancer RNA commits osteogenesis via microRNA-3129 expression in human bone marrow-derived mesenchymal stem cells." Inflamm Regen. 2022 Sep 16;42(1):43. PMID: 36114571
- 2. Te Zhang, Xuming Song, et al. "Aberrant super-enhancer landscape reveals core transcriptional regulatory circuitry in lung adenocarcinoma." Oncogenesis. 2020 Oct 17;9(10):92. PMID: 33070167
- 3. Cho YS, Li S, et al. "CDK7 regulates organ size and tumor growth by safeguarding the Hippo pathway effector Yki/Yap/Taz in the nucleus." Genes Dev. 2020 Jan 1;34(1-2):53-71. PMID: 31857346
- 4. Maritere Urioistegui-Arcos, Rodrigo Aguayo-Ortiz, et al. "Disruption of TFIIH activities generates a stress gene expression response and reveals possible new targets against cancer." bioRxiv. 2019 December 03.
- 5. Kim J, Cho YJ, et al. "CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer." Gynecol Oncol. 2019 Nov 24. pii: S0090-8258(19)31625-7. PMID: 31776040
- 6. Shaj K, Hutcherson RJ, et al. "ATR Kinase Activity Limits Mutagenesis and Promotes the Clonogenic Survival of Quiescent Human Keratinocytes Exposed to UVB Radiation." Photochem Photobiol. 2019 Sep 25. PMID: 31554014
- 7. Sava GP, Fan H, et al. "ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942." Oncogene. 2019 Sep 17. PMID: 31530935
- 8. KAVYA SHAJ. "DIFFERING FUNCTIONS OF ATR KINASE IN HUMAN EPIDERMAL KERATINOCYTES EXPOSED TO ULTRAVIOLET B RADIATION." Wright State University. 2019.
- 9. Seoane M, Buhs S, et al. "Lineage-specific control of TFIIH by MITF determines transcriptional homeostasis and DNA repair." Oncogene. 2019 Jan 16. PMID: 30651597
- 10. Landsverk HB, Sandquist LE, et al. "Regulation of ATR activity via the RNA polymerase II associated factors CDC73 and PNUTS-PP1." Nucleic Acids Res. 2018 Dec 12. PMID: 30541148
- 11. Lin L, Huang M, et al. "Super-enhancer-associated MEIS1 promotes transcriptional dysregulation in Ewing sarcoma in co-operation with EWS-FLI1." Nucleic Acids Res. 2018 Nov 28. PMID: 30496486
- 12. Zanconato F, Battilana G, et al. "Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4." Nat Med. 2018 Oct;24(10):1599-1610. PMID: 30224758
- 13. Chen D, Zhao Z, et al. "Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma." Bone Res. 2018 Apr 4;6:11. PMID: 29644114
- 14. Helga B. Landsverka1, Lise E. Sandquista,et al. "Regulation of ATR activity by the RNA polymerase II phosphatase PNUTS-PP1." bioRxiv.2018.February 16. PMID: 29498802
- 15. Yuan J, Jiang YY, et al. "Super-Enhancers Promote Transcriptional Dysregulation in Nasopharyngeal Carcinoma." Cancer Res. 2017 Dec 1;77(23):6614-6626. PMID: 28951465
- 16. Kemp MG. "DNA damage-induced ATR kinase activation in non-replicating cells is regulated by the XPB subunit of transcription factor II-H (TFIIH). J Biol Chem." 2017 Jun 7. pii: jbc.M117.788406. PMID: 28592488
- 17. Liao R, Mizzen CA. "Site-specific regulation of histone H1 phosphorylation in pluripotent cell differentiation." Epigenetics Chromatin. 2017 May 22;10:29. PMID: 28539972
- 18. Francavilla C, Lupia M, et al. "Phosphoproteomics of Primary Cells Reveals Druggable Kinase Signatures in Ovarian Cancer." Cell Rep. 2017 Mar 28;18(13):3242-3256. PMID: 28355574
- 19. Posternak V, Ung MH, et al. "MYC Mediates mRNA Cap Methylation of Canonical Wnt/β-Catenin Signaling Transcripts By Recruiting CDK7 and RNA Methyltransferase." Mol Cancer Res. 2017 Feb;15(2):213-224. PMID: 27899423
- 20. Harrod A, Fulton J, et al. "Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer." Oncogene. 2017 Apr 20;36(16):2286-2296. PMID: 27748765
Storage | Store at -20°C |
M.Wt | 566.05 |
Cas No. | 1604810-83-4 |
Formula | C31H28ClN7O2 |
Solubility | ≥28.3 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH |
Chemical Name | (E)-N-(3-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)-4-(4-(dimethylamino)but-2-enamido)benzamide |
SDF | Download SDF |
Canonical SMILES | ClC1=CN=C(N=C1C2=CNC3=CC=CC=C23)NC4=CC=CC(NC(C5=CC=C(NC(/C=C/CN(C)C)=O)C=C5)=O)=C4 |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
细胞实验 | |
细胞系 |
Jurkat和Loucy T-ALL细胞系 |
溶解方法 |
在DMSO中的溶解度 >10 mM。为了获得更高的浓度,可以将离心管在37°C加热10分钟和/或在超声波浴中震荡一段时间。原液可以在-20°C以下储存几个月。 |
反应时间 |
72小时;IC50值为50 nM(Jurkat细胞)和0.55 nM(Loucy T-ALL细胞); |
应用 |
作为CDK7的抑制剂,THZ1可以有效地抑制Jurkat和Loucy T-ALL细胞的增殖,IC50值分别为50 nM和0.55 nM。 |
动物实验: | |
动物模型 |
KOPTK1异种移植小鼠 |
剂量 |
10 mg/kg,2次/天,29天。 |
应用 |
在移植人的T-ALL细胞系KOPTK1的生物发光异种移植小鼠模型中,THZ1以10 mg/kg的剂量一天给药两次时耐受性良好,没有观察到体重的下降以及行为上的变化,表明其在动物体内并没有引起明显的毒性效应。 |
注意事项 |
请测试所有化合物在室内的溶解度,实际溶解度和理论值可能略有不同,这是由实验系统的误差引起的,属于正常现象。 |
References: [1] Kwiatkowski N, Zhang T, Rahl P B, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature, 2014, 511(7511): 616-620. |
描述 | THZ1是一种不可逆的,有效的和选择性的CDK7(细胞周期蛋白依赖性激酶7)抑制剂。IC50为3.2 nM。 | |||||
靶点 | CDK7 | |||||
IC50 | 3.2 nM |
质量控制和MSDS
- 批次: